These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 8081029

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Extracellular and intracellular action of clodronate in osteolytic bone diseases? A hypothesis.
    van Rooijen N.
    Calcif Tissue Int; 1993 Jun; 52(6):407-10. PubMed ID: 8369984
    [No Abstract] [Full Text] [Related]

  • 5. Prostate cancer and bone metastases. The effect of clodronate.
    Kylmälä T.
    Ann Chir Gynaecol; 1998 Jun; 87(1):59-60. PubMed ID: 9598233
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Skeletal response to clodronate in prostate cancer with bone metastases.
    Fernández-Conde M, Alcover J, Aaron JE, Ordi J, Carretero P.
    Am J Clin Oncol; 1997 Oct; 20(5):471-6. PubMed ID: 9345330
    [Abstract] [Full Text] [Related]

  • 8. Aredia: the once-monthly infusion for the treatment of bone metastases.
    Lipton A.
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S1-5. PubMed ID: 9801852
    [Abstract] [Full Text] [Related]

  • 9. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
    Kellinsalmi M, Mönkkönen H, Mönkkönen J, Leskelä HV, Parikka V, Hämäläinen M, Lehenkari P.
    Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
    [Abstract] [Full Text] [Related]

  • 10. The potential role of bisphosphonates in prostate cancer.
    Oades GM, Coxon J, Colston KW.
    Prostate Cancer Prostatic Dis; 2002 Dec; 5(4):264-72. PubMed ID: 12627210
    [Abstract] [Full Text] [Related]

  • 11. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts.
    Woo JT, Kawatani M, Kato M, Shinki T, Yonezawa T, Kanoh N, Nakagawa H, Takami M, Lee KH, Stern PH, Nagai K, Osada H.
    Proc Natl Acad Sci U S A; 2006 Mar 21; 103(12):4729-34. PubMed ID: 16537392
    [Abstract] [Full Text] [Related]

  • 12. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
    Muscoso E, Puglisi N, Mamazza C, Lo Giudice F, Testai M, Abbate S, Santangelo A, Panebianco P, Maugeri D.
    Eur Rev Med Pharmacol Sci; 2004 Mar 21; 8(2):97-102. PubMed ID: 15267123
    [Abstract] [Full Text] [Related]

  • 13. A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis.
    Floreani A, Carderi I, Ferrara F, Rizzotto ER, Luisetto G, Camozzi V, Baldo V.
    Dig Liver Dis; 2007 Jun 21; 39(6):544-8. PubMed ID: 17416215
    [Abstract] [Full Text] [Related]

  • 14. Periarticular bone alterations in chronic antigen-induced arthritis: free and liposome-encapsulated clodronate prevent loss of bone mass in the secondary spongiosa.
    Oelzner P, Bräuer R, Henzgen S, Thoss K, Wünsche B, Hersmann G, Abendroth K, Kinne RW.
    Clin Immunol; 1999 Jan 21; 90(1):79-88. PubMed ID: 9884355
    [Abstract] [Full Text] [Related]

  • 15. Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy.
    Elomaa I, Blomqvist C.
    Acta Oncol; 1995 Jan 21; 34(5):629-36. PubMed ID: 7546830
    [Abstract] [Full Text] [Related]

  • 16. Alternative bisphosphonate targets and mechanisms of action.
    Bukowski JF, Dascher CC, Das H.
    Biochem Biophys Res Commun; 2005 Mar 18; 328(3):746-50. PubMed ID: 15694409
    [Abstract] [Full Text] [Related]

  • 17. Parathyroid hormone temporal effects on bone formation and resorption.
    Kroll MH.
    Bull Math Biol; 2000 Jan 18; 62(1):163-88. PubMed ID: 10824426
    [Abstract] [Full Text] [Related]

  • 18. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma.
    Elomaa I, Risteli L, Laakso M, Lahtinen R, Virkkunen P, Risteli J.
    Eur J Cancer; 1996 Jun 18; 32A(7):1166-70. PubMed ID: 8758248
    [Abstract] [Full Text] [Related]

  • 19. The effect of Lodronat(R) on development of osteoporosis in tail-suspended rats.
    Durnova G, Ilyina-Kakueva E, Morukov B.
    J Gravit Physiol; 1997 Jul 18; 4(2):P131-2. PubMed ID: 11540677
    [Abstract] [Full Text] [Related]

  • 20. [Clodronate and myeloma].
    Jantunen E, Lahtinen R, Laakso M.
    Duodecim; 1995 Jul 18; 111(12):1085-7. PubMed ID: 9213542
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.